Investment Thesis
Shuttle Pharmaceuticals faces an acute existential liquidity crisis with approximately 2-3 months of cash runway at current burn rates ($2.4M operating cash burn against only $100K annual revenue), indicating either a pre-clinical/failed program or severely distressed operations. Without immediate substantial capital infusion, the company poses extreme bankruptcy and shareholder dilution risk, with negative operating margins of -2216.8% demonstrating fundamental business model failure.
Strengths
- Minimal long-term debt burden of $426.2K reduces creditor pressure
- Moderate debt-to-equity ratio of 0.13x provides some financial flexibility relative to equity base
- Asset base of $11.8M provides potential liquidation value
Risks
- Critical liquidity crisis: current ratio of 0.30x indicates inability to cover short-term obligations
- Catastrophic cash burn: $2.4M operating cash outflow against $100K revenue represents only 2-3 months of remaining runway
- Existential solvency risk: negative operating margins of -2216.8% and -64.3% ROE indicate fundamental business failure or inadequately financed pre-clinical stage
- Zero insider Form 4 filings in 90 days suggests complete lack of management confidence
- Non-viable unit economics: negative FCF margin of -2436.4% with stagnant revenue growth
Key Metrics to Watch
- Monthly cash burn rate and remaining runway - determines bankruptcy timeline
- Revenue trajectory and path to operating profitability - only fundamental metric that matters for survival
- Capital raise announcements (equity/debt) - sole mechanism to extend solvency without operational turnaround
Financial Metrics
Revenue
100.0K
Net Income
-2.2M
EPS (Diluted)
$-0.43
Free Cash Flow
-2.4M
Total Assets
11.8M
Cash
1.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,216.8%
Net Margin
-2,152.5%
ROE
-64.3%
ROA
-18.2%
FCF Margin
-2,436.4%
Balance Sheet & Liquidity
Current Ratio
0.30x
Quick Ratio
0.30x
Debt/Equity
0.13x
Debt/Assets
71.7%
Interest Coverage
-2.66x
Long-term Debt
426.2K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:17:44.163077 |
Data as of: 2026-03-31 |
Powered by Claude AI